{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:51:09Z","timestamp":1794030669177,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-3059-08-2012"],"award-info":[{"award-number":["KFS-3059-08-2012"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.euo.2021.11.002","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T17:38:58Z","timestamp":1638985138000},"page":"677-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Somatic Features of Response and Relapse in Non\u2013muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin Immunotherapy"],"prefix":"10.1016","volume":"5","author":[{"given":"Jack V.W.","family":"Bacon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Annala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Dugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Herberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Vandekerkhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zellweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bubendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrill A.","family":"Rentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2021.11.002_b0005","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.11.002_b0010","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2021.11.002_b0015","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2021.11.002_b0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.11.002_b0025","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2021.11.002_b0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma","volume":"5","author":"Isharwal","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2021.11.002_b0035","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2021.11.002_b0040","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1158\/0008-5472.CAN-16-0436","article-title":"Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma","volume":"76","author":"Lamy","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2021.11.002_b0045","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.molonc.2016.08.003","article-title":"Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma","volume":"10","author":"Thomsen","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2021.11.002_b0050","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","article-title":"Mutational context and diverse clonal development in early and late bladder cancer","volume":"7","author":"Nordentoft","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2021.11.002_b0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumour tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2021.11.002_b0060","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2021.11.002_b0065","doi-asserted-by":"crossref","first-page":"19539","DOI":"10.1038\/s41598-020-75854-4","article-title":"Recurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship","volume":"10","author":"Marzouka","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2021.11.002_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.euo.2021.11.002_b0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2021.11.002_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euo.2021.11.002_b0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.euo.2021.11.002_b0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"10.1016\/j.euo.2021.11.002_b0095","series-title":"Proceedings of the 9th Python in Science Conference","doi-asserted-by":"crossref","DOI":"10.25080\/Majora-92bf1922-011","article-title":"Statsmodels: econometric and statistical modeling with python","author":"Seabold","year":"2010"},{"key":"10.1016\/j.euo.2021.11.002_b0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.euo.2021.11.002_b0105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euo.2021.11.002_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2021.11.002_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102643","article-title":"Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study","volume":"53","author":"Hosen","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.euo.2021.11.002_b0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.euo.2021.11.002_b0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.euo.2021.11.002_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2021.11.002_b0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JU.0000000000000798","article-title":"A genomic classifier for predicting clinically aggressive luminal bladder tumours with higher rates of pathological up staging","volume":"204","author":"de Jong","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.11.002_b0140","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2021.11.002_b0145","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.bjc.6603850","article-title":"Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation","volume":"97","author":"Kawanishi","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2021.11.002_b0150","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1186\/s12885-015-1859-8","article-title":"Determining the origin of synchronous multifocal bladder cancer by exome sequencing","volume":"15","author":"Acar","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2021.11.002_b0155","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/1878-0261.12746","article-title":"TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer","volume":"14","author":"Hayashi","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2021.11.002_b0160","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumours","volume":"66","author":"L\u00f3pez-Knowles","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2021.11.002_b0165","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2021.11.002_b0170","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/cas.14155","article-title":"Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer","volume":"110","author":"Hirotsu","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.euo.2021.11.002_b0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.11.002_b0180","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry, 2018","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.euo.2021.11.002_b0185","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:54Z","timestamp":1762876134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931121001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2588931121001917"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2021.11.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatic Features of Response and Relapse in Non\u2013muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}